Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Ceapro Inc. (V:CZO)

Business Focus: Biotechnology & Medical Research (NEC)

Mar 28, 2024 07:55 am ET
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the...
Mar 28, 2024 07:55 am ET
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the...
Mar 12, 2024 02:10 pm ET
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals...
Mar 12, 2024 02:10 pm ET
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals...
Feb 26, 2024 07:30 am ET
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmac
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy...
Feb 26, 2024 07:30 am ET
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmac
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy...
Feb 23, 2024 09:00 am ET
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the Company announced it entered into a definitive agreement to combine operations with...
Feb 15, 2024 05:50 pm ET
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting materials (collectively, the “Meeting Materials”)...
Feb 15, 2024 05:50 pm ET
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") today announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead of its special meeting of shareholders to approve its merger of equals transaction with...
Dec 14, 2023 09:40 am ET
Canadian Investment Regulatory Organization Trade Resumption - CZO
VANCOUVER, BC, Dec. 14, 2023 /CNW/ - Trading resumes in:
Dec 14, 2023 07:50 am ET
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement to...
Dec 14, 2023 07:13 am ET
Canadian Investment Regulatory Organization Trading Halt - CZO
VANCOUVER, BC, Dec. 14, 2023 /CNW/ - The following issues have been halted by CIRO
Dec 13, 2023 08:46 am ET
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the...
Nov 29, 2023 09:05 am ET
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Nov 27, 2023 09:15 am ET
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries,...
Nov 07, 2023 08:05 am ET
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries,...
Aug 29, 2023 09:05 am ET
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Aug 25, 2023 09:05 am ET
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of...
Jul 18, 2023 09:05 am ET
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of...
Jul 05, 2023 08:45 am ET
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Jun 07, 2023 09:05 am ET
Ceapro Announces Results of 2023 Shareholders’ Meeting
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all...
May 25, 2023 09:00 am ET
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
May 23, 2023 08:45 am ET
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced encouraging...
May 03, 2023 08:05 am ET
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today positive results...
Apr 27, 2023 08:05 am ET
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment...
Apr 12, 2023 09:00 am ET
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational...
Mar 23, 2023 09:05 am ET
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the...
Mar 08, 2023 08:45 am ET
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the...
Feb 21, 2023 09:00 am ET
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries,...
Jan 11, 2023 01:00 pm ET
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- Live video webcast presentations with participating companies -
Jan 10, 2023 08:05 am ET
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Jan 04, 2023 08:05 am ET
Ceapro Announces Grant of Stock Options
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of...
Dec 22, 2022 09:00 am ET
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from...
Nov 09, 2022 09:00 am ET
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Nov 07, 2022 09:00 am ET
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries,...
Oct 13, 2022 08:35 am ET
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced positive results...
Aug 24, 2022 09:00 am ET
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Aug 11, 2022 09:05 am ET
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced it has entered into an...
Aug 09, 2022 09:00 am ET
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that positive...
Jul 12, 2022 08:35 am ET
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment...
Jun 07, 2022 08:05 am ET
Ceapro Announces Results of 2022 Shareholders’ Meeting
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all...
May 23, 2022 09:00 am ET
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
May 18, 2022 09:00 am ET
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
May 13, 2022 09:00 am ET
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard...
May 11, 2022 09:00 am ET
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that results...
Apr 19, 2022 08:05 am ET
Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment...
Apr 13, 2022 09:00 am ET
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational...
Mar 10, 2022 09:05 am ET
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of...
Mar 02, 2022 08:00 am ET
Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment...
Jan 20, 2022 09:05 am ET
Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Jan 12, 2022 10:35 am ET
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com -
Nov 29, 2021 08:05 am ET
Ceapro Inc. Announces R&D Funding to Support PGX Technology Project
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are...
Nov 17, 2021 09:00 am ET
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Nov 17, 2021 07:00 am ET
Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today reported preliminary...
Nov 11, 2021 08:35 am ET
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update on its...
Nov 10, 2021 09:00 am ET
Ceapro Inc. to Present at the Virtual Investor Roundtable Event
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Nov 04, 2021 02:30 pm ET
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com -- Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies -
Sep 08, 2021 08:00 am ET
Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Aug 26, 2021 09:00 am ET
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Aug 23, 2021 08:05 am ET
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has...
Aug 11, 2021 09:05 am ET
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has entered into a research...
Jun 01, 2021 04:05 pm ET
Ceapro Announces Results of 2021 Shareholders’ Meeting
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all...
May 26, 2021 08:30 am ET
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as a Cholesterol-Lowering Agent
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the completion of patient...
May 20, 2021 09:05 am ET
Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
Apr 22, 2021 09:05 am ET
Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational...
Apr 08, 2021 08:05 am ET
Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful...
Mar 03, 2021 09:05 am ET
Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Jan 14, 2021 09:00 am ET
Ceapro Inc. to Present at NobleCon17
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Jan 08, 2021 08:05 am ET
Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Nov 27, 2020 09:00 am ET
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Oct 22, 2020 08:05 am ET
Ceapro Inc. Announces Increased Financial Contribution from National Research Council of Canada for Innovative PGX Technology Project
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the...
Sep 14, 2020 08:35 am ET
Ceapro Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Aug 20, 2020 09:05 am ET
Ceapro Inc. Reports 2020 Second Quarter and Six-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Aug 18, 2020 08:05 am ET
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic for COVID-19
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update on its...
Aug 04, 2020 09:05 am ET
Ceapro Inc. Announces Publication of Positive Results from Study Evaluating Avenanthramides in Exercise-Induced Inflammation
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that positive...
Jun 22, 2020 08:05 am ET
Ceapro Announces Results of 2020 Shareholders’ Meeting
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all...
Jun 15, 2020 08:35 am ET
Ceapro Inc. Announces Publication of Positive Results for a PGX Processed Drug Delivery System for Accelerated Burn Wound Healing
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that results...
Jun 09, 2020 09:00 am ET
Ceapro Inc. to Present at the Virtual Investor Fireside Chat Series
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
May 28, 2020 09:05 am ET
Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
May 26, 2020 08:35 am ET
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has entered into an...
Apr 16, 2020 09:00 am ET
Ceapro Inc. Reports Fourth Quarter and Full Year 2019 Results and Highlights
Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational...
Apr 15, 2020 07:35 am ET
Ceapro Inc. to Present at the April 2020 Virtual Investor Summit
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Feb 14, 2020 08:00 am ET
Ceapro Inc. Receives Research License from Health Canada Controlled Substances and Cannabis Branch
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received...
Feb 10, 2020 08:47 am ET
Ceapro Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Feb 05, 2020 08:05 am ET
Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received...
Jan 31, 2020 09:00 am ET
Ceapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOF
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its shares...
Jan 06, 2020 09:00 am ET
Ceapro Announces Grant of Stock Options and Restricted Share Units
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options...
Dec 17, 2019 08:00 am ET
Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that results...
Nov 13, 2019 09:00 am ET
Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial...
Oct 29, 2019 08:05 am ET
Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the...
Oct 16, 2019 07:00 am ET
Ceapro Begins Trading on the OTCQX Best Market
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its common shares have...
Oct 16, 2019 07:00 am ET
OTC Markets Group Welcomes Ceapro Inc. to OTCQX
NEW YORK, Oct. 16, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, has qualified to trade on the OTCQX® Best Market.
Sep 25, 2019 08:30 am ET
Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that during a podium...
Sep 10, 2019 08:00 am ET
Ceapro Inc. to Present at the Fall Investor Summit in New York
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc.,...
Aug 28, 2019 09:00 am ET
Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
Aug 27, 2019 08:45 am ET
Ceapro Announces Research Funding Award from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada for Joint Projects with McMaster University
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Canadian Institutes...
Aug 15, 2019 09:00 am ET
Ceapro Inc. Announces Signing of a Contribution Agreement with National Research Council of Canada
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the National Research...
Jun 10, 2019 04:05 pm ET
Ceapro Announces Results of 2019 Shareholders’ Meeting
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors...
Jun 05, 2019 08:00 am ET
Ceapro Presents Positive Results from Avenanthramides Study at the 2019 American Society of Sports Medicine Meeting
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented very...
Jun 03, 2019 09:00 am ET
Ceapro Inc. Commences Patient Enrollment in First-in-Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has commenced patient...
May 23, 2019 09:00 am ET
Ceapro Inc. Reports 2019 First Quarter Financial Results and Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
May 15, 2019 09:00 am ET
Ceapro Inc. Announces Receipt of Site License from Health Canada
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two...
Apr 24, 2019 08:00 am ET
Ceapro Inc. to Present at the ThinkEquity Conference in New York City
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc.,...
Apr 15, 2019 08:05 am ET
Ceapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical Fluids
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that three projects have been...
Apr 11, 2019 09:00 am ET
Ceapro Inc. Reports Fourth Quarter and Full Year 2018 Results and Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and...
Mar 27, 2019 08:05 am ET
Ceapro Announces Acceptance of Abstract for Presentation at the 2019 American College of Sports Medicine Annual Meeting
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the...
Mar 25, 2019 08:00 am ET
Ceapro Inc. Announces Issuance of Indian Patent Application for Enabling Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Office of the...
Feb 26, 2019 08:00 am ET
Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its collaborators from...
Jan 07, 2019 09:00 am ET
Ceapro Announces 2019 Management Team and Grant of Stock Options and Restricted Share Units
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options...
Jan 02, 2019 08:00 am ET
Ceapro Inc. to Present at Biotech Showcase™ 2019
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that  Gilles Gagnon, M.Sc.,...
Dec 12, 2018 09:00 am ET
Ceapro Inc. Presents PGX Technology at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting and Technology Showcase
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Paul Moquin, Ph.D.,...
Nov 21, 2018 09:00 am ET
Ceapro Inc. Reports 2018 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
Nov 19, 2018 08:00 am ET
Ceapro Inc. Announces Completion of Successful Audits by Major Customers
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company’s new...
Oct 23, 2018 08:05 am ET
Ceapro Inc. Receives the 2018 Award for Most Innovative Raw Material at Cosmetics 360 Salon in Paris
Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its new chemical...
Oct 09, 2018 08:00 am ET
Ceapro Inc. Receives Approval from Health Canada to Commence Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from...
Aug 28, 2018 09:00 am ET
Ceapro Inc. Reports 2018 Second Quarter and Six-Month Financial Results and Operational Highlights
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
Aug 27, 2018 08:00 am ET
Ceapro Inc. Settles Judgements in AVAC Ltd. Actions
Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has entered into a...
Jun 27, 2018 08:30 am ET
Ceapro Inc. Announces Publication of Positive Data from Functional Beverage Formulation Study in Journal of Functional Foods
Ceapro Inc.  (TSXV:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the publication of data from...
Jun 13, 2018 07:00 am ET
Ceapro Announces Data from Avenanthramides Study Presented at the Nutrition 2018 Meeting
Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that encouraging data from its study...
Jun 05, 2018 09:00 am ET
Ceapro Announces Results of 2018 Shareholders’ Meeting
Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors...
May 29, 2018 09:00 am ET
Ceapro Inc. Confirms Excellent Bioavailability of its New Water Soluble Chemical Complex Coenzyme Q10-Beta Glucan
Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced positive results from a...
May 24, 2018 09:00 am ET
Ceapro Inc. to Provide a Corporate Update at Its Annual General and Special Meeting of Shareholders on May 29, 2018
Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc.,...
May 17, 2018 09:00 am ET
Ceapro Inc. Reports 2018 First Quarter Results
Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and...
Apr 25, 2018 07:00 am ET
Apr 23, 2018 09:00 am ET
Ceapro Inc. Provides Corporate Update
- Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector over the next 12 months -
Apr 20, 2018 09:00 am ET
Ceapro Inc. Reports 2017 Financial Results
Year marked by increased investments in product pipeline and enabling technologies
Apr 18, 2018 08:05 am ET
Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute
- Beta-glucan project expected to be Ceapro’s first clinical project led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) -
Apr 13, 2018 08:00 am ET
Ceapro Inc. to Present at the 12th International Symposium on Supercritical Fluids
EDMONTON, Alberta, April 13, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will...
Apr 03, 2018 09:00 am ET
Ceapro Announces Acceptance of Abstract for Presentation at the Nutrition 2018 Meeting
EDMONTON, Alberta, April 03, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will...
Mar 15, 2018 09:00 am ET
Ceapro to Present at the Wall Street Investor Forum
Presentation with live webcast on Thursday, March 22nd at 10:20 a.m. ET
Jan 29, 2018 08:00 am ET
Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice C.M. Jones issued his written decision with respect to the two claims brought by AVAC Ltd. ("AVAC") in 2011 and 2012 against Ceapro and certain of its wholly owned subsidiaries.
Jan 29, 2018 07:58 am ET
Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions
Ceapro Inc.  (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice...
Jan 17, 2018 08:00 am ET
Ceapro to Present at Noble Capital Markets' 14th Annual Investor Conference
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro's President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' 14th Annual Investor Conference on Tuesday, January 30 at 2:00 p.m. EST in Fort Lauderdale, FL.
Jan 17, 2018 07:58 am ET
Ceapro to Present at Noble Capital Markets' 14th Annual Investor Conference
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc.,...
Jan 02, 2018 06:00 pm ET
Ceapro Announces Grant of Stock Options and Restricted Share Units
Ceapro Inc. (TSX VENTURE: CZO) today announced the granting of stock options (options) and restricted share units (RSUs) to employees and officers of the Company.
Jan 02, 2018 05:58 pm ET
Ceapro Announces Grant of Stock Options and Restricted Share Units
Ceapro Inc. (TSX VENTURE:CZO) today announced the granting of stock options (options) and restricted share units (RSUs) to employees and officers of the Company. Options to purchase 210,000 common shares were granted pursuant to the...
Nov 15, 2017 09:05 am ET
Ceapro Reports 2017 Third Quarter Business Update and Financial Results
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, 2017 and provided an overview of recent operational highlights.
Nov 15, 2017 09:03 am ET
Ceapro Reports 2017 Third Quarter Business Update and Financial Results
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for...
Oct 26, 2017 08:05 am ET
Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE
- Successful execution of Juvente(DC) Inc. acquisition marks an important step in Ceapro's strategic market diversification business plan -
Oct 26, 2017 08:03 am ET
Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE
Successful execution of JuventeDC Inc. acquisition marks an important step in Ceapro's strategic market diversification business plan - - New anti-aging skin care product line represents $5B market opportunity and utilizes Ceapro's active...
Aug 18, 2017 09:05 am ET
Ceapro Reports 2017 Second Quarter Business Update and Financial Results
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30, 2017 and provided an overview of recent operational highlights.
Aug 18, 2017 09:03 am ET
Ceapro Reports 2017 Second Quarter Business Update and Financial Results
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for...
Jun 05, 2017 05:00 pm ET
Ceapro Announces Results of 2017 Shareholders' Meeting
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 1, 2017.
Jun 05, 2017 04:58 pm ET
Ceapro Announces Results of 2017 Shareholders' Meeting
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed...
Jun 01, 2017 09:25 am ET
Ceapro Inc. Announces its First Major Milestones with its PGX Enabling Technology
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update of the Company's Pressurized Gas eXpanded ("PGX") technology and announced advancements on research projects related to product development and enabling technologies to be presented today during the planned corporate update prior to the start of the Annual General and Special Meeting (AG&SM) of Shareholders.
Jun 01, 2017 09:23 am ET
Ceapro Inc. Announces its First Major Milestones with its PGX Enabling Technology
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update of the Company's...
May 26, 2017 08:05 am ET
Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide a corporate update to on site shareholders on Thursday, June 1, 2017 at 8:30 a.m. MDT at the Westin Hotel, Edmonton, AB. The Company's presentation will be followed by the Annual General and Special Meeting of Shareholders to be held at 10:00 a.m. MDT in the Devonian Room of the
May 26, 2017 08:03 am ET
Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc.,...
May 17, 2017 09:00 am ET
Ceapro Inc. Reports 2017 First Quarter Development Highlights and Financial Results
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three months ended March 31, 2017 and provided a corporate update.
May 17, 2017 08:58 am ET
Ceapro Inc. Reports 2017 First Quarter Development Highlights and Financial Results
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for...
May 04, 2017 08:00 am ET
Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of the first development phase of a project entitled, "Beta glucan with coenzyme Q10 ("CoQ10"): A novel ingredient for functional beverages." This project included two studies, which were conducted at the University of Alberta by Dr. Feral Temelli's team along with Ceapro researchers.
May 04, 2017 07:58 am ET
Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion...
Apr 06, 2017 09:00 am ET
Ceapro Inc. Reports 2016 Financial Results and Provides Corporate Update
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve months ended December 31, 2016 and provided a corporate update. The Company's 2016 financial results reveal the best year in Ceapro's history.
Apr 06, 2017 08:58 am ET
Ceapro Inc. Reports 2016 Financial Results and Provides Corporate Update
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for...
Jan 04, 2017 04:30 pm ET
Ceapro Inc. Announces Conversion of Convertible Debentures to Equity and the Grant of Stock Options
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that holders of $960,000 of convertible debentures due December 31, 2016 have all elected to convert their debentures into common shares at the stated conversion price of $0.64 per common share. Ceapro has subsequently issued 1,499,911 common shares resulting in a significant improvement in the Company's balance sheet.
Jan 04, 2017 04:28 pm ET
Ceapro Inc. Announces Conversion of Convertible Debentures to Equity and the Grant of Stock Options
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that holders of $960,000...
Jan 03, 2017 08:05 am ET
Ceapro Inc. to Present at Biotech Showcase(TM) 2017
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 9th Annual Biotech Showcase(TM) conference on Monday, January 9, 2017 at 3:00 p.m. PT in San Francisco, CA.
Jan 03, 2017 08:03 am ET
Ceapro Inc. to Present at Biotech Showcase(TM) 2017
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at...
Nov 23, 2016 07:03 am ET
Ceapro Inc. Reports Third Quarter 2016 Financial and Operational Results
Continued to deliver strong performance, surpassing the full year 2015 financial results by the third quarter of 2016 Announced opening of new facility in Edmonton Awarded "Company of the Year" by Bio Alberta...
Nov 14, 2016 10:30 am ET
Crystal Research Associates, LLC Issues Executive Informational Overview on Ceapro Inc.
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Ceapro Inc. (TSX VENTURE: CZO). The full 64-page report is available on Crystal Research Associates' website at...
Sep 28, 2016 08:05 am ET
Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its new 30,000-square-foot bioprocessing extraction/manufacturing facility in Edmonton, Alberta, Canada.
Sep 28, 2016 08:03 am ET
Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its...
Sep 27, 2016 07:05 am ET
Ceapro Inc. Awarded 2016 BioAlberta Achievement Award for Company of the Year
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has been awarded the 2016 BioAlberta Achievement Award for Company of the Year.
Sep 27, 2016 07:03 am ET
Ceapro Inc. Awarded 2016 BioAlberta Achievement Award for Company of the Year
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has been...
Sep 21, 2016 08:05 am ET
Ceapro Inc. Awarded Research Grant from German-Canadian Centre for Innovation and Research
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the German-Canadian Centre for Innovation and Research ("GCCIR") has made a non-reimbursable grant contribution of $250,000 for the commercialization advancement of Ceapro's Pressurized Gas eXpanded (PGX) technology. This grant will match Ceapro's contribution as part of a $1.5 million project involving three German based organizations
Sep 21, 2016 08:03 am ET
Ceapro Inc. Awarded Research Grant from German-Canadian Centre for Innovation and Research
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the German-Canadian...
Sep 13, 2016 08:05 am ET
Ceapro Inc. Announces Allowance of Canadian Patent for Enabling Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has received allowance from the Canadian Patent Office for Canadian Patent Application Serial No. 2,794,960 entitled, "Supercritical Fluid Treatment of High Molecular Weight Biopolymers." Upon issuance, this patent which was filed as part of the International Patent Cooperation Treaty (PCT) will provide intellectual property
Sep 13, 2016 08:03 am ET
Ceapro Inc. Announces Allowance of Canadian Patent for Enabling Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has...
Aug 24, 2016 08:05 am ET
Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30, 2016 and provided an overview of recent operational highlights.
Aug 24, 2016 08:03 am ET
Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for...
Jul 14, 2016 08:00 am ET
Ceapro Inc. Closes Final Tranche of a Brokered Private Placement
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the second and final tranche of its previously announced brokered private placement (the "Offering"). The second tranche resulted in the issuance of 4,085,370 units (each, a "Unit"), including 20,000 Units held in escrow pending final approval of the Offering by the TSX Venture Exchange, each issued at a price of
Jul 14, 2016 07:58 am ET
Ceapro Inc. Closes Final Tranche of a Brokered Private Placement
Ceapro Inc.  (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed...
Jul 11, 2016 08:00 am ET
Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the first tranche of its previously announced brokered private placement (the "Offering") and increased the maximum size of the Offering from $5,750,000 to $10,000,000. The first tranche resulted in the issuance of 5,348,592 units (each, a "Unit"), including 405,500 Units held in escrow pending final approval of
Jul 11, 2016 07:58 am ET
Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the...
Jul 07, 2016 09:25 am ET
Ceapro Inc. Announces No Material Change
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and active ingredients for healthcare and cosmetic industries, is issuing this press release in response to a recent request by the Investment Industry Regulatory Organization of Canada ("IIROC") to comment on recent trading activity in its stock.
Jul 07, 2016 09:23 am ET
Ceapro Inc. Announces No Material Change
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and active ingredients for healthcare and cosmetic industries, is issuing this press release in response to a recent request...
Jun 09, 2016 07:05 am ET
Ceapro Inc. Announces Brokered Private Placement
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed Echelon Wealth Partners Inc. ("Echelon" or the "Agent") as sole agent to undertake a brokered private placement financing, on a commercially reasonable basis, of 4,716,981 units (each, a "Unit") at a price of $1.06 per Unit for gross proceeds to the Company of $5,000,000 (the "Offering").
Jun 09, 2016 07:03 am ET
Ceapro Inc. Announces Brokered Private Placement
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed...
Jun 02, 2016 04:05 pm ET
Ceapro Announces Election of Directors at 2016 Shareholders' Meeting
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 1, 2016.
Jun 02, 2016 04:03 pm ET
Ceapro Announces Election of Directors at 2016 Shareholders' Meeting
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed...
May 18, 2016 08:00 am ET
Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three-months ended March 31, 2016 and provided a business update.
May 18, 2016 07:58 am ET
Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for...
May 09, 2016 08:00 am ET
Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany.
May 09, 2016 07:58 am ET
Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this...
Apr 18, 2016 07:35 am ET
Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a 2016 business outlook.
Apr 18, 2016 07:33 am ET
Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the...
Apr 14, 2016 07:35 am ET
Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company's History
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company's 2015 Financial Results reveal the best year in Ceapro's history.
Apr 14, 2016 07:33 am ET
Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company's History
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for...
Apr 06, 2016 07:05 am ET
Ceapro Announces Renewal of a Long Term License and Distribution Agreement With Symrise
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or "the Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro's high value active ingredients to major key international players in the cosmetic market.
Apr 06, 2016 07:03 am ET
Ceapro Announces Renewal of a Long Term License and Distribution Agreement With Symrise
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or "the Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long...
Mar 01, 2016 10:15 am ET
Ceapro Inc. Announces Research Partnership with McMaster University for Its Pressurized Gas Expanded (PGX) Technology
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company will initiate an extensive research program in collaboration with McMaster University to develop novel chemistries for stabilizing Ceapro's Pressurized Gas eXpanded (PGX) derived products.